| abstract |
ABSTRACT OF THE DISCLOSURE 3,4-Dihydro-quinazoline derivatives having the follow-ing formula, their pharmaceutically acceptable salts and compsotions obtained therefrom. The compounds possess anti-allergic activity as is shown by their activity in the passive cutaneous anaphylaxis (PCA) test in rats, and thus are useful in the prevention and treatment of bronchial asthma, allergic rhinitis, hay fever, urticaria and dermatosis, even when orally administered. |